Date published: 2026-4-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

CLCA5_Clac5 Inhibitors

The chemical class known as CLCA5_CLAC5 Inhibitors comprises a specialized group of compounds that interact with and modulate the activity of the CLCA5 protein. As a member of the chloride channel accessory (CLCA) family, CLCA5 is believed to play a role in modulating calcium-activated chloride channels (CaCCs) in specific cellular contexts. Inhibitors within this class are carefully developed to target specific regions or binding sites within CLCA5, with the aim of influencing its functional activity or protein-protein interactions involved in chloride channel regulation. The primary objective of CLCA5_CLAC5 Inhibitors is to fine-tune the intricate regulatory mechanisms related to chloride channel conductance, a critical process that maintains cellular homeostasis and signaling. By selectively engaging CLCA5, these inhibitors have the potential to modulate CaCCs' activity, which plays essential roles in various physiological processes, such as neuronal excitability, smooth muscle contraction, and ion transport across epithelial tissues.

The development and characterization of CLCA5_CLAC5 Inhibitors hold promise in providing deeper insights into the functional roles of CLCA5 within cellular environments. By elucidating the specific effects of CLCA5 inhibition on chloride channel regulation, researchers can gain a more comprehensive understanding of the broader physiological and pathophysiological implications associated with CLCA5 activity.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Niflumic acid

4394-00-7sc-204820
5 g
$32.00
3
(1)

Niflumic acid is a non-steroidal anti-inflammatory drug (NSAID) that has been found to inhibit CLCA2 activity.

Indomethacin

53-86-1sc-200503
sc-200503A
1 g
5 g
$29.00
$38.00
18
(1)

Indomethacin is another NSAID that has been reported to inhibit CLCA2 activity.

Benzamil•HCl

161804-20-2sc-201070
50 mg
$195.00
1
(0)

Benzamil is a selective inhibitor of the epithelial sodium channel (ENaC), which has been reported to inhibit CLCA2-mediated chloride transport.

Flufenamic acid

530-78-9sc-205699
sc-205699A
sc-205699B
sc-205699C
10 g
50 g
100 g
250 g
$27.00
$79.00
$154.00
$309.00
1
(1)

Flufenamic acid is an NSAID that has been shown to inhibit chloride ion channels, including CLCA2.

5-Nitro-2-(3-phenylpropylamino)benzoic Acid (NPPB)

107254-86-4sc-201542
sc-201542B
sc-201542A
10 mg
25 mg
50 mg
$109.00
$193.00
$317.00
7
(1)

NPPB is a compound that has been found to inhibit chloride channels, including CLCA2.

CFTR Inhibitor-172

307510-92-5sc-204680
sc-204680A
10 mg
50 mg
$168.00
$520.00
10
(1)

CFTRinh-172 is a selective inhibitor of the CFTR chloride channel, which indirectly affects CLCA2 activity.

T16Ainh-A01

552309-42-9sc-497578
sc-497578A
10 mg
50 mg
$69.00
$283.00
(0)

T16Ainh-A01 is a selective inhibitor of the calcium-activated chloride channel TMEM16A (ANO1), which shares functional similarities with CLCA2.

Bumetanide (Ro 10-6338)

28395-03-1sc-200727
sc-200727A
1 g
5 g
$109.00
$228.00
9
(1)

Bumetanide is a loop diuretic that has been reported to inhibit chloride ion transport, potentially affecting CLCA2 activity.